Lenacapavir and Encorafenib: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Lenacapavir
Encorafenib
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir
Interaction Deep Dive
Coadministration of lenacapavir (SUNLENCA®), a CYP3A substrate, together with a strong CYP3A inducer is contraindicated due to significantly reduced lenacapavir exposure, which may result in the loss of therapeutic effect and development of resistance to lenacapavir1, however lenacapavir (YEZTUGO®) and a strong CYP3A inducer can be used concomitantly with dosage adjustments. For individuals receiving YEZTUGO® and initiating therapy with a strong CYP3A inducer, continue to maintain scheduled injection dosing (YEZTUGO® 927 mg SUBQ once every 6 months) plus administer the following supplemental YEZTUGO® doses: administer 927 mg SUBQ and 600 mg orally on the day of strong CYP3A inducer initiation (at least 2 days after YEZTUGO® is first initiated), then administer 600 mg orally the day after strong CYP3A inducer initiation. Dosing recommendations are not available for the initiation of YEZTUGO® in individuals already receiving strong CYP3A inducers, nor in individuals receiving the weekly oral dosage. If a strong CYP3A inducer is coadministered for longer than 6 months, continue to administer supplemental doses of YEZTUGO® every 6 months (26 weeks +/- 2 weeks) from CYP3A inducer initiation. After stopping a strong CYP3A inducer, continue the once every 6 months scheduled injection dosing of YEZTUGO® 2.
Why it happens (mechanism)
Induction of CYP3A-mediated metabolism of lenacapavir
Literature reports
1 report — tap to read
Common questions
Can I take Lenacapavir and Encorafenib together?
Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Always confirm with your pharmacist or prescriber before making any change.
How serious is the Lenacapavir and Encorafenib interaction?
It is rated contraindicated. These should generally not be used together.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Lenacapavir or Encorafenib need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (2)
- Product Information: SUNLENCA(R) oral tablets, subcutaneous injection, lenacapavir oral tablets, subcutaneous injection. Gilead Sciences Inc (per FDA), Foster City, CA, 2024. DailyMed
- Product Information: YEZTUGO(R) oral tablets, subcutaneous injection, lenacapavir oral tablets, subcutaneous injection. Gilead Sciences Inc (per manufacturer), Foster City, CA, 2025. DailyMed
Keep reading about Lenacapavir
Keep reading about Encorafenib
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist